Terms: = Liver cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
1516 results:
1. Predicting effect of anti-pd-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
[TBL] [Abstract] [Full Text] [Related]
2. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and pd-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract] [Full Text] [Related]
3. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
[TBL] [Abstract] [Full Text] [Related]
4. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
[TBL] [Abstract] [Full Text] [Related]
5. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
[TBL] [Abstract] [Full Text] [Related]
6. Homologous-magnetic dual-targeted metal-organic framework to improve the Anti-hepatocellular carcinoma efficacy of pd-1 inhibitor.
Guo H; Li X; Mao D; Wang H; Wei L; Qu D; Qin X; Li X; Liu Y; Chen Y
J Nanobiotechnology; 2024 Apr; 22(1):206. PubMed ID: 38658950
[TBL] [Abstract] [Full Text] [Related]
7. Loss of Y in regulatory T lymphocytes in the tumor micro-environment of primary colorectal cancers and liver metastases.
Wójcik M; Juhas U; Mohammadi E; Mattisson J; Drężek-Chyła K; Rychlicka-Buniowska E; Bruhn-Olszewska B; Davies H; Chojnowska K; Olszewski P; Bieńkowski M; Jankowski M; Rostkowska O; Hellmann A; Pęksa R; Kowalski J; Zdrenka M; Kobiela J; Zegarski W; Biernat W; Szylberg Ł; Remiszewski P; Mieczkowski J; Filipowicz N; Dumanski JP
Sci Rep; 2024 Apr; 14(1):9458. PubMed ID: 38658633
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.
Xu L; Chen J; Liu C; Song X; Zhang Y; Zhao H; Yan S; Jia W; Wu Z; Guo Y; Yang J; Gong W; Ma Y; Yang X; Gao Z; Zhang N; Zheng X; Li M; Su D; Chen M
BMC Med; 2024 Apr; 22(1):172. PubMed ID: 38650037
[TBL] [Abstract] [Full Text] [Related]
9. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab.
Zhang C; Wang G; Liu N; Li T; Zhu J; Hou H
Front Immunol; 2024; 15():1387465. PubMed ID: 38646529
[TBL] [Abstract] [Full Text] [Related]
10. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma.
Zhu W; Zhang Z; Chen J; Chen X; Huang L; Zhang X; Huang X; Ma N; Xu W; Yi X; Lu X; Fu X; Li S; Mo G; Wang Y; Yuan G; Zang M; Li Q; Jiang X; He Y; Wu S; He Y; Li Y; Hou J
Signal Transduct Target Ther; 2024 Apr; 9(1):101. PubMed ID: 38643203
[TBL] [Abstract] [Full Text] [Related]
11. Anti-pd-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
[TBL] [Abstract] [Full Text] [Related]
12. HAIC Combined with lenvatinib plus pd-1 versus lenvatinib Plus pd-1 in patients with high-risk advanced HCC: a real-world study.
Chang X; Li X; Sun P; Li Z; Sun P; Ning S
BMC Cancer; 2024 Apr; 24(1):480. PubMed ID: 38627684
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial.
Li Z; Liu J; Zhang B; Yue J; Shi X; Cui K; Liu Z; Chang Z; Sun Z; Li M; Yang Y; Ma Z; Li L; Zhang C; Sun P; Zhong J; Zhao L
Nat Commun; 2024 Apr; 15(1):3260. PubMed ID: 38627377
[TBL] [Abstract] [Full Text] [Related]
14. The pd-1/PD-L1 Axis in the Biology of MASLD.
Pipitone RM; Lupo G; Zito R; Javed A; Petta S; Pennisi G; Grimaudo S
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612483
[TBL] [Abstract] [Full Text] [Related]
15. The predictive value of PD-L1 expression in response to anti-pd-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis.
Yoon SB; Woo SM; Chun JW; Kim DU; Kim J; Park JK; So H; Chung MJ; Cho IR; Heo J
Front Immunol; 2024; 15():1321813. PubMed ID: 38605964
[TBL] [Abstract] [Full Text] [Related]
16. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
Yarchoan M; Gane EJ; Marron TU; Perales-Linares R; Yan J; Cooch N; Shu DH; Fertig EJ; Kagohara LT; Bartha G; Northcott J; Lyle J; Rochestie S; Peters J; Connor JT; Jaffee EM; Csiki I; Weiner DB; Perales-Puchalt A; Sardesai NY
Nat Med; 2024 Apr; 30(4):1044-1053. PubMed ID: 38584166
[TBL] [Abstract] [Full Text] [Related]
17. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis.
Gudd CLC; Mitchell E; Atkinson SR; Mawhin MA; Turajlic S; Larkin J; Thursz MR; Goldin RD; Powell N; Antoniades CG; Woollard KJ; Possamai LA; Triantafyllou E
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580334
[TBL] [Abstract] [Full Text] [Related]
18. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract] [Full Text] [Related]
19. Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging.
Scheuermann S; Kristmann B; Engelmann F; Nuernbergk A; Scheuermann D; Koloseus M; Abed T; Solass W; Seitz CM
Front Immunol; 2024; 15():1383932. PubMed ID: 38566984
[TBL] [Abstract] [Full Text] [Related]
20. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving pd-1 inhibitor combinational therapy.
Zeng Y; Huang J; Pang J; Pan S; Wu Y; Jie Y; Li X; Chong Y
Front Immunol; 2024; 15():1330644. PubMed ID: 38558804
[TBL] [Abstract] [Full Text] [Related]
[Next]
